pharma · Metastatic Solid Tumor · Advanced or Metastatic Solid Tumors · HOWL
Werewolf Therapeutics
Werewolf Therapeutics patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Milton, GB
- Founded
- 2017
- Employees
- 53
- Programs
- 2
- Drugs
- 0
- Patents
- 10
Werewolf Therapeutics patents
10 pharmaceutical patents indexed for Werewolf Therapeutics. 0 expire within 24 months.
Werewolf Therapeutics has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12275769
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 12076371
Activatable cytokine polypeptides and methods of use thereof
granted -
US 12036266
Activatable cytokine polypeptides and methods of use thereof
granted -
US 11981716
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11739132
Separation moieties and methods of use thereof
granted -
US 11535658
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 11453710
Activatable interleukin 12 polypeptides and methods of use thereof
granted -
US 11352403
Activatable interleukin-2 polypeptides and methods of use thereof
granted -
US 10696723
Activatable interleukin 12 polypeptides
granted -
US 10696724
Activatable interleukin-2 polypeptides
granted
Frequently asked questions
How many patents does Werewolf Therapeutics have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Werewolf Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.